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Abstract: The ethanol extract from Vernonia polyanthes leaves (EEVP) was investigated 
for antinociceptive and anti-inflammatory effects at the doses (p.o.) of 100, 200 and 400 mg/kg 
in animal models. The extract reduced the number of abdominal contortions by 16.75% 
and 31.44% at a dose of 200 and 400 mg/kg, respectively. The results obtained showed that 
EEVP exerted a significant antinociceptive effect in the two phases of formalin. The EEVP 
increased the reaction time on a hot plate at the doses of 100, 200 and 400 mg/kg after  
90 min of treatment. The paw edema was reduced by EEVP at the doses of 100, 200 and 
400  mg/kg  after  4  h  of  application  of  carrageenan.  Doses  of  200  and  400  mg/kg, 
administered 4 h before the carrageenan injection, significantly reduced the exudate volume 
(29.25 and 45.74%, respectively) and leukocyte migration (18.19 and 27.95%, respectively). 
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These  results  suggest  that  V.  polyanthes  can  be  an  active  source  of  substances  with 
antinociceptive and anti-inflammatory activities. 
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1. Introduction 
Inflammation is a reaction of the body against an aggressive agent, characterized by vasodilatation 
and access of fluid and cells to the target tissue [1]. One of the major signs of inflammation is the pain 
that can be triggered by direct stimulation of nociceptors or by the action of inflammatory mediators [2]. 
These  mediators,  for  example  cytokines,  histamine,  serotonin,  leukotrienes  and  prostaglandins, 
increase the vascular permeability and the migration of leukocytes to inflamed tissue [2]. In addition, 
different pathologic processes, such as cardiovascular and metabolic disorders [3–5], peptic ulcer [6] 
and  cancer  [7] are  related to inflammation. The  usual treatment of inflammatory pain is done  by  
non-steroidal anti-inflammatory drugs, but the adverse effects described as irritation of gastric mucosa 
and ulcer, water retention and nephrotoxicity prevent the use of these agents [8]. On the other hand, 
medicinal  plants  have  been  widely  used  in  traditional  medicine  to  treat  different  inflammatory 
conditions [9]. However, the pharmacological properties and identifying the active compounds of these 
plants are needed to ensure its effectiveness and safety of users based on scientific support. 
The genus Vernonia, one of the largest and most important member of the Asteraceae family, is 
represented by approximately 1500 species [10]. Plants of this genus, as Vernonia polyanthes Less, are 
found in South America, and have been traditionally used as diuretic, hypotensive, antihemorragic, 
sedative, abortive, anthelmintic, antiulcerogenic, antirheumatic, cicatrizing and anti-inflammatory [11,12]. 
Among different studies of Vernonia, the investigations regarding antinociceptive and anti-inflammatory 
effects are particularly important [13–15]. 
V. polyanthes Less (Asteraceae), known as assa-peixe, have been studied and their pharmacological 
properties  such  as  antihypertensive  and  diuretic  [12,16],  antiulcerogenic  [17],  antifungal  and 
leishmanicidal [18] and antimycobacterial [19] have been established. However, the antinociceptive 
and anti-inflammatory activities were not previously reported using this plant. Fixed acids, alkaloids, 
aminoacids, coumarins, steroids, triterpenes, anthraquinones, flavonoids, saponins and tannins were 
detected in infusions of V. polyanthes [20] and may be responsible for their pharmacological effects. 
Considering the medicinal use for treatment of rheumatism, cicatrisation and inflammation and the 
lack scientific validation supported in pharmacological and clinical studies, the present investigation 
was designed to evaluate the antinociceptive and anti-inflammatory effects of EEVP using experimental 
animal models. In addition, preliminary phytochemical screening was conducted in order to determine 
the presence of the main classes of constituents in this extract. Int. J. Mol. Sci. 2012, 13  3889 
 
 
2. Results and Discussion 
2.1. Acute Toxicity 
At the doses administered per oral route (p.o.), the EEVP was toxic to animals with LD50 of 2.78 g/kg 
(95% confidence intervals 1.67–4.64 g/kg). However, in the evaluated period, the animals did not 
show  cyanosis,  piloerection,  writhing,  ptosis,  tremors,  convulsions,  ataxia,  hypnosis,  red  urine  or 
diarrhea. There were not alteration when considered the parameters motor activity, respiration, corneal 
reflex, righting and withdrawal, body tone and amount of pats.  
2.2. Acetic Acid-Induced Writhing Response in Mice 
The treatment of animals with EEVP (200 and 400 mg/kg, p.o.) produced a significant (p < 0.01 
and p < 0.001, respectively) and dose-dependent inhibition in abdominal writhes produced by acetic 
acid (Table 1). The control group produced 66.37 ±  2.19 abdominal contortions. 
Table 1. Effects of the ethanol extract from Vernonia polyanthes leaves (EEVP) on acetic 
acid-induced writhing in mice. 
Group  Dose (mg/kg)  Number of writhes  Inhibition (%) 
Control  Saline  66.37 ±  2.19  - 
  100  64.62 ±  2.44  2.64 
EEVP  200  55.25 ±  2.39 **  16.75 
  400  45.50 ±  2.44 ***  31.44 
Indomethacin  10  22.62 ±  1.91 ***  65.92 
Acetylsalicylic acid  200  20.62 ±  1.69 ***  68.93 
Data are mean ±  S.E.M. of eight mice. ** p < 0.01, *** p < 0.001 vs. control group. 
2.3. Formalin-Induced Paw Licking in Mice 
In  Figure  1,  it  is  shown  that  pretreatment  with  morphine  (5  mg/kg)  or  with  the  extract  of  
V. polyanthes (200 and 400 mg/kg, p.o.) produced significant changes of paw licking time in the first 
phase of pain response. In the second phase, a dose-dependent and significant (p < 0.05 or p < 0.001) 
reduction in licking time was observed in mice treated with EEVP (100, 200 and 400 mg/kg, p.o.)  
as well as with indomethacin (10 mg/kg, p.o.) and morphine (5 mg/kg, s.c.). For the control group, the 
time spent was 80.87 ±  3.47 s and 85.50 ±  3.19 s in the first and second phases, respectively.  
2.4. Effects on Hot-Plate Latency Assay in Mice 
Due to the analgesic effect observed in the first phase of formalin test, we decided to evaluate the 
EEVP using hot plate test, a model of central antinociceptive activity. After 90 min of treatment, doses 
of 100 (p < 0.01), 200 (p < 0.001) and 400 mg/kg (p < 0.001) increased significantly the latency time 
in the respective control group (Figure 2). Morphine proved to be a potent analgesic, increasing the 
latency time within the evaluation periods. Naloxone, an opioid antagonist, blocked the morphine 
action but did not alter the antinociceptive effect of the EEVP. Int. J. Mol. Sci. 2012, 13  3890 
 
 
Figure 1. Effects of the EEVP on formalin-induced nociception in mice. First phase = 0–5 min 
after formalin injection; second phase = 15–30 min. Data are mean ±  S.E.M. of eight mice. 
** p < 0.01; *** p < 0.001 vs. control group. 
 
Figure 2. Effects of the EEVP on the latency time of mice exposed to the hot plate test. 
Data are mean ±  S.E.M. of eight mice. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control group. 
 
2.5. Effects on Carrageenan-Induced Edema in Rats 
The activity of the EEVP on carrageenan-induced edema in rat is shown in Table 2. After 2 h of 
carrageenan  application,  the  paw  edema  was  reduced  in  16.95  and  22.03%  at  the  doses  of  200  and  
400 mg/kg, respectively. Edema inhibition was observed 3 and 4 h after injection of carrageenan at the 
doses  of  100  mg/kg  (12.50  and  16.40%;  p  <  0.05,  respectively),  200  mg/kg  (16.41  and  27.87%;  
p < 0.05 and p < 0.01, respectively) and 400 mg/kg (25.78 and 31.97%; p < 0.01 and p < 0.001, 
respectively) when compared with control group. In these times, indomethacin (reference drug) also 
inhibited the paw edema (28.12 and 36.06%, respectively). Int. J. Mol. Sci. 2012, 13  3891 
 
 
Table 2. Effects of the EEVP on carrageenan-induced paw edema in rats. 
Group  Dose 
(mg/kg) 
Volume of hind paw (mL) 
1 h  2 h  3 h  4 h 
Control  Saline  1.05 ±  0.08  1.18 ±  0.08  1.28 ±  0.06  1.22 ±  0.06 
  100  0.97 ±  0.06  1.03 ±  0.04  1.12 ±  0.05 *  1.02 ±  0.08 * 
EEVP  200  0.92 ±  0.06  0.98 ±  0.05 *  1.07 ±  0.04 *  0.88 ±  0.04 ** 
  400  0.85 ±  0.04  0.92 ±  0.05 *  0.95 ±  0.04 ***  0.83 ±  0.04 *** 
Indomethacin  10  0.82 ±  0.05  0.85 ±  0.06 **  0.92 ±  0.05 ***  0.78 ±  0.04 *** 
Data are mean ±  S.E.M. of six rats. * p < 0.05, **p < 0.01, *** p < 0.001 vs. control group. 
2.6. Effects on Carrageenan-Induced Pleurisy in Rats 
The pleurisy effects demonstrated that doses of 200 (p < 0.05) and 400 mg/kg (p < 0.001) of EEVP 
significantly reduced the exudate volume in 13.83 and 43.08% (Table 3) when compared with control 
group. The number of total leukocytes was also inhibited at the doses of 200 (17.87%; p < 0.001) and 
400  mg/kg  (28.39%;  p  <  0.001)  (Table  3)  in  comparison  to  the  respective  control.  Indomethacin 
reduced the exudate volume and the leukocyte migration. 
Table 3. Effects of the EEVP on number of leukocytes in carrageenan-induced pleurisy  
in rats. 
Group  Dose  
(mg/kg) 
Exsudate volume  
(mL) 
Inhibition 
(%) 
N°  Leukocytes  
(10
3 cells/mm
3) 
Inhibiti
on (%) 
Control  Saline  1.88 ±  0.08  -  15.50 ±  0.50  - 
  100  1.78 ±  0.08  5.32  14.90 ±  0.43  3.87 
EEVP  200  1.62 ±  0.04 *  13.83  12.73 ±  0.21 ***  17.87 
  400  1.07 ±  0.05 ***  43.08  11.10 ±  0.32 ***  28.39 
Indomethacin  10  0.73 ±  0.09 ***  61.17  9.87 ±  0.35 ***  36.32 
Data are mean ±  S.E.M. of six rats. * p < 0.05, *** p < 0.001 vs. control group. 
2.7. Phytochemical Screening 
Phytochemical  screening  of  the  ethanol  extract  indicated  the  presence  of  flavonoids,  tannins, 
coumarins, terpenoids, sterols, saponins and alkaloids. 
The present study assessed the pharmacological effects of the leaves of V. polyanthes, a medicinal 
plant reputed in Brazilian folk medicine for its anti-inflammatory and cicatrizing properties [11,12]. 
Based  on  popular  reports,  the  EEVP  was  prepared  and  screened  for  their  antinociceptive  and  
anti-inflammatory effects using  classical  models  of nociception in  mice and inflammation in  rats. 
Therefore, considering the results of pharmacological tests observed in the present investigation, the 
EEVP  has  antinociceptive  and  anti-inflammatory  effects  and  this  is  the  first  report  described  in  
the literature. 
The acute toxicity test showed that the doses of EEVP were toxic to mice. Based in this result, the 
pharmacological  dose  (400  mg/kg  maximal  dose),  not  described  previously  in  the  literature,  
was  defined  from  the  LD50.  The  toxic  effects  have  been  described  on  plants  of  the  genus  Int. J. Mol. Sci. 2012, 13  3892 
 
 
Vernonia [13,14,21–24]. It is possible that the toxic effect of the EEVP could be due to the presence of 
phytochemical compounds as saponins detected in this study [24,25].  
The writhing test is an experimental model used for the screening of drugs with analgesic activity, 
based on the irritation caused after intraperitoneal injection of 0.6% acetic acid. The writhing response 
is considered to be a visceral inflammatory pain model [26], and in this way, this acid causes the 
release of pain mediators such as bradykinin, prostaglandins, histamine and serotonin in the peritoneal 
fluid of mice [27]. In the present study, we clearly showed a dose-related antinociceptive effect of 
EEVP in the writhing test and probably this action could be due the presence of bioactive substances. 
This action could be mediated by peripherical effects, including the prostaglandin synthesis inhibition. 
According  to  the  Figure  1,  the  EEVP  produced  significant  inhibition  in  the  both  phases  of  
formalin-induced  pain  from  the  200  mg/kg.  The  formalin  test  is  a  valid  and  reliable  model  of 
nociception  and  is  sensitive  for  various  classes  of  analgesic  drugs.  This  test  produced  a  distinct 
biphasic response and different analgesics may act differentially in the first and second phases [28].  
It is considered a model to clinical pain because it causes a local tissue injury to the paw and is also 
indicative of tonic and localized inflammation pain. Moreover, this model can be used to clarify the 
possible mechanism of antinociceptive effect of a proposed analgesic [29]. Centrally acting drugs such 
as opioids inhibit both phases equally [30]. But peripherally acting drugs such as aspirin, indomethacin 
and  dexamethasone  only  inhibit  the  late  phase.  The  second  phase  seems  to  be  an  inflammatory 
response with inflammatory pain that can be inhibited by anti-inflammatory drugs [28,31]. Substance P 
and  bradykinin  act  as  mediators  in  the  first  phase,  while  histamine,  serotonin,  prostaglandin  and 
bradykinin are involved in the nociceptive response of the second stage [30].  
In the hot plate test, a central model that has a selectivity for opioid-derived analgesics [32], oral 
treatment with EEVP exerts an antinociceptive action confirming the central activity observed in the 
first phase of formalin test (100, 200 and 400 mg/kg). This test is also considered to be sensitive to 
drugs  acting  at  the  supraspinal  modulation  level  of  the  pain  response  [33],  suggesting  at  least  a 
modulatory effect of the investigated extract. Our results indicate that the analgesia induced by the 
EEVP is not dependent on the opioid system, since previous treatment with naloxone did not change 
the observed data (Figure 2). 
Carrageenan  induced  paw  edema  is  an  experimental  model  of  acute  inflammation  involving 
different phases [34]. The first phase (1–2 h) is related with the release of serotonin and histamine; 
kinins play a role in the middle phase [33], while prostaglandins appear to be the most important 
mediators  in  the  second  phase  (3–5  h)  of  the  postcarrageenan  response  [35–37].  Based  on  this 
explanation, it could be argued that the suppression of the first phase may be due to inhibition of the 
release of early mediators, such as histamine and serotonin, and the action in the second phase may be 
explained  by  an  inhibition  of  cyclooxygenase.  Therefore,  the  present  result  indicates  that  ethanol 
extract (100, 200 and 400 mg/kg, p.o.) and indomethacin play a crucial role as protective factors 
against the carrageenan-induced acute inflammation. 
The injection of carrageenan into the pleural cavity of rats elicited an acute inflammatory response, 
characterized by the accumulation of fluid containing large number of leukocytes [38–40]. It is an 
interesting method that evaluates the leukocyte migration during the inflammatory process. Non-steroidal 
anti-inflammatory drugs, such as indomethacin, inhibit the accumulation of exudates and mobilization 
of leukocytes between 3 and 6 h after application of carrageenan [39,41]. In our experiment, the EEVP Int. J. Mol. Sci. 2012, 13  3893 
 
 
in  the  pleurisy  model  clearly  showed  the  inhibition  of  the  formation  of  pleural  exudate  and  the 
leukocyte migration (Table 3). 
Studies have been reported the antinociceptive and anti-inflammatory effects of plants of the genus 
Vernonia [13–15]. Among the active compounds identified in this important genus, the highlights are 
the  flavonoids  [42–44].  In  our  investigation,  phytochemical  screening  showed  the  presence  of 
numerous constituents’ classes, such as flavonoids, tannins, coumarins, terpenoids, sterols, saponins 
and alkaloids. Considering this chemical diversity, pharmacological effects could be attributed to the 
tannins  and  flavonoids,  since  these  constituents  are  well  established  as  antinociceptive  and/or  
anti-inflammatory agents [45–47]. However, complementary studies are necessary to determine the 
better correlation between activities and chemical composition of V. polyanthes. 
3. Experimental Section 
3.1. Plant Material and Extraction 
The plant material used in the present study was collected in Juiz de Fora, Minas Gerais State, 
Southeast region of Brazil, in March 2009. The species was identified by Dr. Fá tima Regina Gonç alves 
Salimena  and  a  voucher specimen (CESJ  number 10.329) was deposited in  the Herbarium  of the 
Federal University of Juiz de Fora, Brazil. Dried and powdered leaves (450 g) were exhaustively 
extracted in 95% ethanol (2.5 L) by static maceration for 3 weeks at room temperature with renewal of 
solvent every 2 days. The EEVP was filtered and evaporated under a rotary evaporator at controlled 
temperature (50–60 ° C). This material was placed in a desiccator with silica to yield 36.68 g. The dried 
extract was dissolved using 1% DMSO in normal saline for pharmacological studies. 
3.2. Chemicals 
Drugs  and  reagents  used  in  this  study  (and  their  sources)  were  as  follows:  acetic  acid  and 
acetylsalicylic acid (Vetec Quí mica Farm Ltda, Rio de Janeiro, RJ, Brazil), formaldehyde (Reagen 
Quimibrá s  Ind.  Quí mica  S.A.,  Rio  de  Janeiro,  RJ,  Brazil),  morphine  hydrochloride  (Merck  Inc., 
Whitehouse Station, NJ, USA), naloxone and indomethacin (Sigma Chemical Co, St Louis, MI, USA). 
3.3. Animals 
Male Wistar rats (90–110 days) weighing 200–240 g and male Swiss albino mice (50–70 days) 
weighing 25–30 g were used in the experiments. The animals were provided by the Central Biotery of 
the Federal University of Juiz de Fora. The animals were divided into groups and kept in plastic cages 
(47 ×  34 ×  18 cm) under a 12 h light/12 h dark cycle at room temperature (22 ±  2 ° C), with free access 
to Purina rations and water. Animal care and the experimental protocol followed the principles and 
guidelines  suggested  by  the  Brazilian  College  of  Animal  Experimentation  (COBEA)  and  were 
approved by the local ethical committee (protocol number 053/2009). 
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3.4. Acute Toxicity 
Groups of ten mice received oral doses of 0.5, 1, 1.5, 2 and 3 g/kg of EEVP, while the control group 
received the vehicle (saline). The groups were observed for 48 h and mortality at end of this period 
was recorded for each group [48]. The LD50 (50% lethal dose) was determined by probit test using the 
log of the dose versus probit [49]. The determination of LD50 served to define the doses used in the 
experiments of pharmacological activities. 
3.5. Writhing Test 
Antinociceptive activity was evaluated on the acetic acid-induced writhing according to Collier et al. 
protocol [26]. Male Swiss albino mice were divided into groups of eight mice. The animals were 
pretreated with EEVP (100, 200, and 400 mg/kg, p.o.) or acetylsalicylic acid (200 mg/kg, p.o.) and 
indomethacin  (10  mg/kg,  p.o.)  used  as  standard  drugs,  one  hour  prior  to  intraperitoneal  (i.p.)  of  
0.6% v/v acetic acid (0.1 mL/10 g). Ten minutes after i.p. injection of acetic acid, the number of 
writhing during the following 20 min were counted. Control mice received 1% DMSO in sterile saline 
orally (10 mL/Kg). 
3.6. Formalin Test 
The  method  previously  described  by  Hunskaar  and  Hole  [28]  was  used.  Pain  was  induced  by 
injecting of 20 µL of 2.5% formalin (37% formaldehyde) in sterile saline in the subplantar right hind 
paw region. Male mice were divided into groups of eight mice each. Extract was administered orally at 
doses of 100, 200, and 400 mg/kg body wt., 60 min before formalin injection. The control group 
received 1%  DMSO in  sterile saline orally (10 mL/kg), while indomethacin (10 mg/kg, p.o.) and 
morphine  (5  mg/kg  subcutaneous)  were  used  as  positive  controls.  The  animals  were  observed  to 
evaluate the licking time (an index of nociception) during the first phase, neurogenic (0–5 min), and 
the second phase, inflammatory (15–30 min), after formalin injection. 
3.7. Hot-Plate Test 
The hot plate test was carried out according to the method described by Eddy and Leimbach [50]. 
Mice were placed on a hot plate (Model LE 7406, Letica Scientific Instruments, Barcelona, Spain) 
maintained at 55 ±  1 ° C.  Latency of nociceptive response such as licking, flicking of a hind limb or 
jumping was measured. Three groups of mice  (n = 8) were treated p.o. with EEVP (100, 200 or  
400 mg/kg; 0.1 mL per 10 g body weight); the control group received 1% DMSO in sterile saline  
(10 mL/kg). Measurements were performed at time 0, 30, 60 and 90 min after drug administration, 
with a cut-off time of 40 s to avoid lesions to the animals’ paws. The effect of pretreatment with 
naloxone  (1  mg/kg,  subcutaneously)  on  the  analgesia  produced  by  the  EEVP  (400  mg/kg)  was 
determined in a separate group of animals. Morphine (5 mg/kg, subcutaneously), in the absence and 
presence of naloxone treatment, was used as a reference. 
 
 
 Int. J. Mol. Sci. 2012, 13  3895 
 
 
3.8. Carrageenan-Induced Paw Edema 
According to the method described by Winter et al. [51], the paw edema volume of the rats was 
measured using a plethysmometer (model LE 7500, Letica Scientific Instruments, Barcelona, Spain). 
Male  Wistar  rats  were  divided  into  groups  of  six  animals  which  received,  p.o.,  doses  of  EEVP  
(100,  200 and  400 mg/kg;  0.1 mL per 10  g body  weight), 1% DMSO in  saline or  indomethacin  
(10 mg/kg) 1 h before the injection of carrageenan. The animals were anesthetized with cetamine and 
xylazine (60 mg/kg and 8 mg/kg, respectively) 30 min before the injection of 0.1 mL of 2% (w/v) 
carrageenan into the subplantar region of the right hind paw for the induction of edema. In the left hind 
paw, used as a control, 0.1 mL of sterile saline was injected. The volume of paw edema, recorded three 
times, was measured at 1, 2, 3 and 4 h after carrageenan injection. The measure of edema was made by 
the difference between the volume displaced by the right paw and the left paw.  
3.9. Carrageenan-Induced Pleurisy 
Rats were anesthetized with cetamine and xylazine (60 mg/kg and 8 mg/kg, respectively) and a 
suspension of saline containing 2% carrageenan (0.4 mL) were injected into the pleural cavity [41]. 
EEVP (100, 200 and 400 mg/kg), 1% DMSO in saline or indomethacin (10 mg/kg, p.o.) were given  
60 min before injection of the irritant. At 4 h after the injection of carrageenan, the animals were killed 
by overdose of  cetamine and xylazine (120 mg/kg and 16 mg/kg, respectively), and the skin  and 
pectoral muscles were retracted. A longitudinal incision was made between the third and fifth ribs on 
each side of the mediastinum. The exudate was collected and transferred to a 15 mL conical centrifuge 
tube and the total volume determined. A 20 µL aliquot of the exudate was used to determine the total 
leukocyte count in Neubauer chambers. 
3.10. Phytochemical Screening of the EEVP 
Phytochemical screening of the EEVP was performed to detect the eventual presence of different 
classes of constituents, such as alkaloids, flavonoids, anthraquinones, coumarins, saponins, terpenes 
and tannins using specific reactions [52]. 
3.11. Statistical Analysis 
Data are expressed as mean ±  S.E.M. Statistical significance was determined by one-way analysis 
of  variance  followed  by  the  Student–Newman–Keuls  test.  P  values  below  0.05  were  considered 
significant. The percentage of inhibition was calculated by using 
100 − T ×  100/C (%) or T ×  100/C − 100 (%) 
where C and T indicate non-treated (vehicle) and drug-treated, respectively. 
4. Conclusions 
Our  results  clearly  demonstrated  that  the  EEVP  displayed  significant  antinociceptive  and  
anti-inflammatory effects in mice and rats models. In addition, these results provided an initial scientific 
validation of popular use of this plant as a medicine against dolorous and inflammatory processes. Int. J. Mol. Sci. 2012, 13  3896 
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